Products for Research Use Only

Stapokibart

CAT: 0804-HY-P990093-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P990093-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively) . Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) [1][2].
CAS Number
2734715-10-5
Product Name Alternative
CM310
UNSPSC
12352203
Target
Interleukin Related; STAT
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/stapokibart.html
Purity
99.37
Solubility
10 mM in DMSO
Smiles
[Stapokibart]
Molecular Weight
(144.3 kDa)
References & Citations
[1]Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1) : a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.|[2]Liu W, et al. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024 Aug 13;27 (9) :110721.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Isoform
IL-13; IL-4; STAT6